Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Norway
Study Details
Study Description
Brief Summary
Despite the significant preventive efforts to reduce HIV infections in the past decades, the incidence in MSM has plateaued at a higher level after the turn of the millennium. In 2015 a reduction in newly diagnosed HIV cases was reported for the first time. Early detection of HIV and treatment as prevention may have played a positive role in reducing HIV transmission, however, numbers increased again in 2016. Over 90% of HIV positive MSM in Norway are treated and virologically suppressed and thereby considered not infectious.
Since the early days of the HIV epidemic, changes in sexual behaviour and increased use of condoms have been advocated and the only tools available to prevent HIV transmission. Later, frequent testing and treatment of STIs (including HIV) have been added to the preventive measures available. Still, this does not seem to be sufficient for all MSM. The use of PrEP is therefore likely an important supplement to prevent HIV infections in MSM at high risk for HIV acquisition.
The main objective of this study is to monitor the impact of PrEP on the subject's psychological and sexual health. It is also important to monitor the adherence to PrEP, development of drug resistance (in the case of undetected HIV infection at initiation of PrEP), frequency of other STIs, changes in sexual behaviour, recreational drug use and quality of life. PrEP has proven to be effective in reducing the sexual acquisition of HIV, however this requires that the medication is taken as prescribed, whilst the subject is exposed to high risk of infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This study is designed to evaluated implementation of PrEP treatment as a part of the general HIV preventive program in Norway. The target groups are mainly MSM and transgender persons at high risk of HIV infection, as well as other subjects at risk of HIV infection due to their sexual practices.
Objectives include assessment of the following:
-
Assess the impact of PrEP on the sexual and psychological health of PrEP users Incidence of sexually transmitted infections (STIs) in PrEP users compared to those not taking PrEP
-
Assessment of drug compliance
-
Incidence of HIV seroconversion despite PrEP
-
Frequency and development of drug resistance in subjects who HIV-seroconvert (if any)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| PrEP Group Subject offered to start PrEP treatment in routine clinical practice |
|
| Control Group Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study. Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2) Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort. |
Outcome Measures
Primary Outcome Measures
- Impact of PrEP [24 months]
Assess the impact of PrEP on the sexual and psychological health of PrEP users
Secondary Outcome Measures
- Incidence of STIs [24 months]
Incidence of sexually transmitted infections (STIs) in PrEP users compared to those not taking PrEP
- Drug compliance [24 months]
Assessment of drug compliance
- HIV seroconversion [24 months]
Incidence of HIV seroconversion despite PrEP
- Drug resistance [24 months]
Frequency and development of drug resistance in subjects who HIV-seroconvert
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male, female or transgender persons aged ≥ 18 years who are offered or have started PrEP in routine clinical practice, and 2, 3, 4, 5, 6 or 7 (below).
-
Men who have sex with men (MSM) and transgender persons;
-
who have had unprotected anal sex with two or more partners during the last six months and/or
-
who have had bacterial sexually transmittable infection(s) during the last twelve months and/or
-
who have used post-exposure prophylaxis(PEP) during the last twelve months and/or
-
who use recreational drugs when having sex
-
Indication for PrEP is present according to the assessment of the health care provider
-
Men and women who are at high risk of HIV according to their sexual practices
-
HIV-negative partner of a HIV-positive person not yet virologically suppressed by antiretroviral therapy (ART)
-
Sex workers with inconsistent condom use
-
Persons with inconsistent condom use with sexual partners in / from countries with a high prevalence of HIV (COHP)
Exclusion Criteria:
-
HIV positive subjects
-
Subjects who cannot take Emtricitabine/tenofovir disoproxil combination tablet (FTC/TDF) due to contraindications
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Helse Bergen HF - Haukeland universitetssykehus | Bergen | Norway | ||
| 2 | Sørlandet sykehus HF | Kristiansand | Norway | ||
| 3 | Olafia Clinic,Oslo University Hosptial | Oslo | Norway | 0424 | |
| 4 | Akershus universitetssykehus HF | Oslo | Norway | ||
| 5 | Brynsenglegene | Oslo | Norway | ||
| 6 | Dept. Inf. Diseases, Oslo University Hospital | Oslo | Norway | ||
| 7 | Helse Stavanger HF - Stavanger universitetssjukehus | Stavanger | Norway | ||
| 8 | Universitetssykehuset Nord-Norge HF | Tromsø | Norway | ||
| 9 | Helse Midt-Norge St Olavs Hospital | Trondheim | Norway |
Sponsors and Collaborators
- Oslo University Hospital
Investigators
- Principal Investigator: Anne Olaug Olsen, MD PhD, Oslo University Hospital
Study Documents (Full-Text)
More Information
Publications
None provided.- 2017/759